Kamar na Rahoton Pfizer-BioNTech “placebo”. Daga watan Yulin da ya gabata saboda wasu dalilai ya sake yin yawo, wannan lokaci ne mai kyau don magance wani muhimmin daki-daki wanda ban rufe shi ba a cikin rahoton na asali kuma wanda aka yi watsi da shi a cikin tattaunawar, wani lokacin mai zafi, tattaunawar da ta biyo baya. "Placebo" ba wai yana nufin maganin gishiri ba. Placebo a cikin wannan mahallin zai iya zama ma'anar "babu mRNA:" watau bayani mai kunshe da dukkan sinadaran maganin sai dai mRNA wanda ya kamata a cushe a cikin nanoparticles na lipid wanda ke aiki azaman tsarin bayarwa a dandalin BioNTech. Lipids ba su da komai: ba su da abin da za su iya bayarwa. “Kayan aikin magani,” mRNA, ya ɓace.
Ko da yake ba su fito sun fadi haka ba, amma ga dukkan alamu wannan shi ne abin da malaman kimiyyar sinadarai na Jamus da na ambata suka yi tunani a kai. Jigon rahoton na shine ba Shahararriyar binciken sauye-sauyen rukunin Danish na yanzu, wanda ya gano cewa batches daban-daban na allurar Pfizer-BioNTech suna da alaƙa da nau'ikan guba daban-daban, sun rushe zuwa manyan ƙungiyoyin "blue", "kore," da "rawaya", kamar yadda aka wakilta a cikin jadawali na ƙasa.
Babban abin da ya fi mayar da hankali kan rahotona shi ne binciken da malaman Jamus suka yi cewa, duk sai ɗaya daga cikin rukunin “rawaya”, waɗanda kusan ba su da lahani ga bayanan Danish, ba su kasance ƙarƙashin gwajin sarrafa inganci daga hukumar da ke da alhakin sakin batch a cikin EU: wato Cibiyar Paul Ehrlich ta Jamus (PEI).
Kamar yadda Farfesa Gerald Dyker ya lura a cikin hira da 'yar jaridar Jamus Milena Preradovic, wannan yana ba da goyan baya ga zato cewa batches na rawaya "wani abu ne kamar placebos," watau kamar dai PEI sun sani a gaba cewa batches ba su da lahani kuma don haka ba sa buƙatar gwaji. An gwada dukkanin (mai guba) batches "blue" kuma haka ma yawancin (mai guba) "kore" ne.
Amma a cikin hirar, Farfesa Dyker ya ci gaba da cewa wani abu dabam:
Bugu da ƙari, wannan watakila ma wani yanki ne na bayanai wanda ke da ban sha'awa ga masu sauraro. Ta "placebos," muna tunanin maganin saline a cikin yanayin injections da kwayoyin sukari a cikin kowane nau'i na allunan. [Amma] Dangane da dokar EU na kwanan nan… placebos na iya ƙunsar duk abubuwan da ake buƙata. Dole ne kawai ainihin abu mai aiki ya ɓace. Kuma wannan yana nufin a cikin wannan yanayin cewa duk abin da za a iya sanya a ciki. An ba da izinin ƙirƙirar Nanoparticle. RNA da aka gyara kawai dole ne a ɓace a lokacin.
Don haka, shin shahararrun batches "rawaya" a cikin binciken Danish sun ƙunshi komai sai mRNA?
Asalin buguwar labarina ya tunzura yunƙurin "ɓata" hasashen placebo. Wadannan sun mayar da hankali, a gefe guda, akan da'awar cewa batches na "rawaya" sun kasance a haƙiƙa suna da alaƙa da mafi girman adadin abubuwan da ba su da kyau fiye da binciken Danish kuma, a gefe guda, akan iƙirarin cewa bayanan Danish yana da shekaru. Kamar yadda na nuna nan, Duk waɗannan ƙin yarda, a kan bincikar muhawara da bayanai, a fili sun gaza.
A gefe guda, "debunkings", a gefe guda, sun yi watsi da mummunar alaƙar da ke tsakanin batches na "rawaya" kusan mara lahani da batches waɗanda PEI, a matsayin hukumar sakin batch, ta kasa gwadawa. Amma tsammanin batches na "rawaya" sun haifar da wasu abubuwa masu banƙyama fiye da abin da za a iya tsammani daga halayen psychogenic kawai zuwa harbin saline, wannan, ba shakka, za a iya bayyana shi ta hanyar masu haɓakawa. Bayan haka, ƙwayoyin nanoparticles da kansu an san suna da alaƙa da guba. Ko da komai na lipids zai haifar da wasu munanan halayen.
Yiwuwar batches na "rawaya" sun ƙunshi komai amma mRNA yana nuna haɗin gwiwa, musamman, tsakanin mai sarrafa Jamusanci, PEI, da kamfanin Jamus BioNTech. (Don takamaiman dalilan da ya sa irin wannan haɗin kai ba zai zama abin mamaki ba, duba labarina nan.) BioNTech shine mai haɓakawa kuma mai mallakar dandamalin mRNA da aka yi amfani da shi a cikin harbin Pfizer-BioNTech kuma, ba kamar Amurka ba, ana tsammanin yana aiki tare da masu kwangila, don samar da duk mRNA da aka yi amfani da shi a cikin EU tana samarwa kanta.
Wannan ya fito fili daga cikakkun bayanai na sigar da ba a gyara ba na Babban Yarjejeniyar Siyayya (APA) da aka kammala tsakanin Hukumar Turai da haɗin gwiwar Pfizer-BioNTech. Sashe na I.6.3 na APA, wanda yake samuwa nan, karanta:
Ana samar da allurar rigakafi a Turai da farko za ta fito ne daga rukunin masana'antar Pfizer a Puurs, Belgium kuma za ta haɗa da RNA da aka samar a rukunin masana'anta na BioNTech gami da rukunin yanar gizon da masu kwangilar ke aiki a Jamus…
Amma bayan sanya sunayen 'yan kwangilar, sashin da ya dace na APA ya ci gaba da tantancewa:
...duk da haka dan kwangila na iya kerawa da samarwa daga wurare a wajen Turai, inda ya dace don hanzarta samar da kayayyaki…
Dalilin wannan keɓanta shine sanannun ƙullun da ke shafar wadatar Pfizer-BioNTech EU a farkon, saboda gaskiyar cewa BioNTech ya sami damar kammala siyan babban sikelin sa na farko. masana'anta a Marburg bayan samun izini. "Kayan aiki a wajen Turai" babu shakka yana nufin masana'antar Pfizer a Andover, Massachusetts, inda Pfizer ke kera mRNA a ƙarƙashin lasisi daga BioNTech.
Yanzu mun san cewa batches na "blue" masu guba a cikin binciken Danish an fara fitar da su da farko, batches na "kore" masu guba daga baya, kuma kusan batches na "rawaya" na ƙarshe. Don haka, batches na "blue" na iya ƙunshi mRNA daga kayan aikin Pfizer-Andover, batches na "kore" mRNA - watakila a ƙaramin sashi ko canza ta wata hanya - daga cibiyar BioNTech-Marburg, kuma "rawaya" batches ba mRNA kwata-kwata?
Wannan ya haifar da ƙarin tambaya bi da bi: Shin wadatar Amurka tana nuna irin wannan tsarin na raguwar yawan guba? Ko gubar wadatar Amurka, mai ɗauke da mRNA daga Pfizer-Andover, ta kasance mai dorewa akan lokaci?
-
Robert Kogon shi ne sunan alkalami na wani ɗan jarida da ake bugawa da yawa wanda ke yin rubuce-rubuce kan al'amuran Turai.
Duba dukkan posts
